Lumosa Therapeutics partners with Camargo Pharmaceutical Services for the development of its analgesic in the US

Taipei, Taiwan-based Lumosa Therapeutics Co., Ltd., a company focused on developing treatments for neurological and inflammatory disease, announced recently that it had engaged Cincinnati-headquartered Camargo Pharmaceutical Services for regulatory consulting and strategic development services for LT1001 (Naldebain®, dinalbuphine sebacate IM injection) in the US.

Read more

Aslan Pharmaceuticals announces collaboration with Taiwan’s leading genomic research institute

Singapore-headquartered ASLAN Pharmaceuticals (ASLAN, 6497.TT), a biotech company focused on the development of immunotherapies and targeted treatments for Asia prevalent cancer types, recently announced the signing of a research collaboration agreement with Academia Sinica’s Genomic Research Centre, one of Taiwan’s eminent research institutions.

Read more